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Abstract
Changes in mitochondrial fatty acid metabolism may underlie the decline in cardiac function in the hypothyroid animals.
The effect of hypothyroidism on fatty acid oxidation, carnitine–acylcarnitine translocase activity and lipid composition in
rat heart mitochondria has been examined. Rates of mitochondrial fatty acid oxidation as well as carnitine-carnitine and
carnitine–palmitoylcarnitine exchange reactions were all depressed in heart mitochondria isolated from hypothyroid rats.
Kinetic analysis of the carnitine–carnitine exchange reaction showed that the hypothyroid state affects the V of thismax
process, while having no effect on the K value. Heart mitochondrial inner membrane lipid composition was significantlym
 .altered in hypothyroid rats. Cardiolipin, particularly, was found to decrease by around 36% . Alterations in fatty acid
pattern of mitochondrial inner membrane preparations from hypothyroid rats were also found. The effects of the
hypothyroid state on fatty acids oxidation, carnitine translocase activity and phospholipid composition were completely
reversed by following treatment of hypothyroid rats with thyroid hormone. A lower cardiolipin content in the mitochondrial
inner membrane offers a plausible mechanism to explain the decline in the translocase activity in hypothyroidism. q 1997
Elsevier Science B.V.
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1. Introduction
Thyroid hormones have been recognised as one of
the major factors involved in the regulation of cardiac
function. Hyperthyroidism causes tachycardia,
whereas hypothyroidism induces bradycardia. Mito-
chondria are considered to be likely subcellular target
of thyroid hormone action in view of their central
role in the regulation of energy production.
Thyroid hormones have been reported to affect
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reactions in almost all pathways of lipid metabolism
 w x.for review, see 1 . Fatty acids are the major sub-
strate for oxidative metabolism in heart muscle, and
indeed the oxidation of fatty acids tends to take
precedence over the oxidation of glucose or pyruvate
w x2 . An important site of control of fatty acyl-CoA
oxidation is the mechanism that transport cytoplasmic
fatty acyl-CoA to the fatty acyl-CoA dehydrogenase
in the mitochondrial matrix. Carnitine is an absolute
requirement for the transport of activated long chain
w xacyl units into the mitochondria 3 . Short, branched
and medium chain acyl units, however can be acti-
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vated within the mitochondrial matrix and their sub-
sequent oxidation is carnitine-independent.
The inner mitochondrial membrane contains a spe-
cific protein system for the transport of carnitine and
w xacyl-carnitine known as carnitine translocase 4–6 .
The carnitine translocase exchanges cytosolic acyl-
carnitine or free carnitine for carnitine in the mito-
chondrial matrix. The kinetic properties and the sub-
strate specificity of this carrier system have been
w xinvestigated in intact mitochondria 6,7 . More re-
cently, the carnitine carrier has been isolated and its
activity reconstituted in artificial membranes such as
w xliposomes 8 . An essential requirement of cardiolipin
for mitochondrial carnitine–acylcarnitine translocase
w xactivity has been demonstrated 8,9 .
We have recently reported that the activity of
several anion carrier proteins is decreased in heart
w xmitochondria isolated from hypothyroid rats 10,11 .
Changes in the mitochondrial cardiolipin content have
been considered as possible factor responsible for this
effect. Moreover, it has been very recently reported
that mitochondrial cardiolipin biosynthesis is under
w xthyroid hormone control 12,13 .
Alterations in the carnitine–acylcarnitine translo-
case activity under different physiopathological con-
ditions have been described. Enhancement of mito-
chondrial carnitine acylcarnitine translocase activity
w x w xunder ketogenic 14 and hyperthyroid conditions 15
whereas deficit of this translocase activity in aging
w x w x16,17 and ischemia 18 have been reported. To date
there has been no report assessing heart mitochon-
drial carnitine–acylcarnitine translocase activity rela-
tive to the hypothyroid state. These considerations
have prompted us to examine the effect of hypothy-
roid state on carnitine–acylcarnitine translocase activ-
ity, fatty acids oxidation and phospholipid composi-
tion in rat heart mitochondria.
2. Materials and methods
2.1. Chemicals
w 14 xL- methyl- C -carnitine hydrochloride was pur-
 .chased from Du Pont De Nemours Deutchland .
L-carnitine hydrochloride, palmitoyl-L-carnitine, pal-
mitoyl-CoA, acetyl-DL-carnitine, mersalyl acid and
all other reagents were of the highest quality avail-
able and were purchased from Sigma, St. Louis, MO.
2.2. Animals
 .Male wistar rats 200–250 g , housed at tempera-
ture of 228C and fed at libitum with a standard diet
were used throughout these studies. Animals were
made hypothyroid by adding 6-n-propyl-2-thiouracil
 .PTU; 0.05%, wrv to their drinking water for 3–4
w xweeks 11,19 . For thyroid hormone treatment of rats
 Xpretreated with PTU, a dose of T 3,3 ,5-tiiodo-L-3
.thyronine of 25mgr100 g body weight was injected
intraperitoneally for 2 days. Control animals received
only the solvent for the same period. Animals were
killed 24 h after final administration.
2.3. Mitochondrial preparation
Rat heart mitochondria were prepared by differen-
tial centrifugation of heart homogenate essentially as
w xdescribed previously 20 . Mitochondria were sus-
 .pended in 0.25 M sucroser5 mM Tris–HCl pH 6.8
and stored in ice. The yield of mitochondrial proteins
 .mgrg heart wet wt within each group of animals
was consistent, suggesting minimal variation in the
preparation of the mitochondrial fractions. The mito-
chondria used in the present work showed high respi-
 .ratory control ratios above 7, using malate 0.5 mM
 .and pyruvate 2 mM , added simultaneously, as respi-
ratory substrates.
Rat heart mitoplasts were prepared according to
w x21 . Mitochondrial protein concentration was mea-
sured by the usual biuret method using serum albu-
min as standard.
2.4. Measurements of rates of O consumption2
Mitochondrial respiratory parameters were mea-
sured at 258C with f0.5 mg mitochondrial protein in
a 1.5 ml water-jacketed cell and O consumption was2
measured with a Clark oxygen electrode connected to
a suitable recorder. The respiratory medium consisted
of 120 mM KCl, 20 mM Na-Hepes, 1 mM MgCl ,2
1 mM EDTA, 5 mM phosphate; final pH was 7.4.
Rates of state 3 respiration, induced by adding ADP
 .2 mM , were evaluated from the linear slopes of
oxygen uptake versus time plots.
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2.5. Carnitine–acylcarnitine translocase acti˝ity
 .Freshly isolated mitochondria 30–40 mg protein
w 14 xwere loaded with 2 mM L- methyl- C -carnitine
 .spec. act. ;7,200 dpmrnmol in 20 ml of a medium
containing 0.2 M mannitol and 20 mM Hepes pH
.7.4 . After 5 min. of preincubation, mitochondria were
centrifuged at 08C for 10 min at 15,000=g. The
resulting pellet was rinsed twice with 15 ml of the
above medium before it was suspended in 0.2 M
mannitol. The carnitine–acylcarnitine translocase ac-
tivity was measured essentially as described by Pande
w xand Parvin 6 . Efflux of radiolabelled carnitine was
w14 xinitiated at 08C by addition of C -carnitine-loaded
 .mitochondria f0.5 mg protein to 0.5 ml, 200 mM
 .mannitol and 50 mM Tris pH 7.4 containing unla-
belled carnitine or palmitoylcarnitine. The exchange
reaction was stopped after 1 min. of incubation, which
was the linear time of the exchange, by addition of
1 mM mersalyl followed by rapid centrifugation of
the mitochondrial suspension and measurement of
radioactivity in the supernatant and pellet. Mitochon-
drial inhibitors rotenone, oligomycin and antimycin A
were included throughout the loading and assay pro-
cedure to dissociate carnitine–acylcarnitine transport
from electron transport and oxidative phosphoryla-
tion. Rates of exchange were calculated as described
w xby Pande and Parvin 6 .
2.6. Analysis of lipids in mitoplast preparations
Phospholipid and fatty acids were analysed by
 .high-pressure liquid chromatography HPLC using a
Beckman 344 gradient liquid chromatograph. Lipids
from heart mitoplasts were extracted with chloro-
formrmethanol by the procedure of Bligh and Dyer
w x22 . Phospholipids were separated by the HPLC
w xmethod previously described 23 with an Altex ultra-
 .sil-Si columns 4.6=250 mm . The chromatographic
system was programmed for gradient elution using
two mobil phases: solvent A, hexaner2-propanol
 .6r8, vrv and solvent B, hesaner2-propanolrwater
 .6r8r1.4,vrvrv . The percentage of solvent B in
solvent A was increased in 15 min. from 0 to 100%.
Flow rate was 2 mlrmin. and detection at 206 nm.
To analyse fatty acids, heart mitoplasts were
saponified with 5% KOH in 50% aqueous methanol
for 40 min. at 908C. After acidification, the solution
was first extracted with chloroform, then dried and
then esterified with m-methoxyphenancylbromide for
HPLC analysis. For this analysis, the column was an
Altex Ultrasphere-ODS reverse phase 4.6 =
.250 mm ; the mobile phase was tetrahydrofuranr
 .acetonitrilerwater 45r25r35, vrvrv at a flow rate
of 2 mlrmin.
2.7. Statistical analysis
Results are expressed as mean values"standard
error. Statistical significances were determined by the
Student t-test.
3. Results
The results of experiments on fatty acid oxidation
in heart mitochondria isolated from control, hypothy-
roid and hypothyroid rats treated with T hormone3
are presented in Table 1. Rates of ADP-induced O2
consumption with palmitoylcarnitine were signifi-
 .cantly lower around 35% in mitochondria from
hypothyroid rats than those obtained with mitochon-
dria from control rats. The lowered-rates of palmi-
toylcarnitine oxidation observed in mitochondria from
hypothyroid rats were completely restored to normal
levels by treating the hypothyroid rat with T . Very3
similar results were obtained when palmitoylcarnitine
was replaced by two other fatty acids respiratory
substrate combinations such as palmitoyl–CoAq
carnitine or acetylcarnitine.
In order to define more closely the step limiting
the rate of O consumption with palmitoylcarnitine2
and presumably the locus of the hypothyroidism-
linked decrement, the oxidation of octanoate was
measured in mitochondria from control and hypothy-
roid rats. This substrate is thought to penetrate the
mitochondrion as such and does not require the par-
ticipation of the carnitine carrier for its oxidation
w x16 . Rates of O consumption in the presence of2
octanoate were only slightly decreased in mitochon-
dria from hypothyroid rats, the degree of this de-
 .crease being much lower 18% than that found with
 .palmitoylcarnitine 35% . The oxidation of palmitoyl-
carnitine differs from that of octanoate in that it
requires the participation of the mitochondrial carni-
tine carrier. Thus, the fact that the rates of oxygen
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Table 1
Rates of fatty acid oxygen consumption by heart mitochondria isolated from control, hypothyroid and hypothyroidqT -treated rats3
 .  .Substrates mM Rates of O consumption ng atoms Orminrmg protein2
Control Hypothyroid HypothyroidqT3
a .Palmitoyl-L-carnitine 0.02 284"32 185"19 296"34
a .  .Palmitoyl-CoA 0.01 qcarnitine 5 248"26 164"18 254"28
b .Acetyl-DL-carnitine 5 255"27 168"19 266"30
a P-0.01.
b P-0.05 vs. control.
Rates of state 3 mitochondrial respiration were measured polarographically in a medium containing the standard reagents as described
under Section 2 and in addition 2 mM malate. When a steady state of O consumption was obtained, fatty acid substrates were added at2
concentrations indicated and after 1 min respiration was stimulated by the addition of 2 mM ADP. Each value represents the
mean"S.E.M. for four separate experiments with two rats for each group.
consumption in hypothyroid animals are much slower
in the presence of palmitoylcarnitine than with oc-
tanoate, would suggest a possible involvement of the
carnitine carrier in this effect. This possibility is
directly examined below.
The activity of carnitine–acylcarnitine translocase
was measured in heart mitochondria from control and
hypothyroid rats. The carnitine–acylcarnitine translo-
Fig. 1. Rates of carnitine–carnitine exchange in heart mitochon-
dria isolated from control, hypothyroid and hypothyroidqT -3
treated rats. Rates of carnitine–carnitine exchange in heart mito-
w14 xchondria were measured by addition of C -carnitine-loaded
mitochondria to 0.5 ml of basal medium containing different
concentrations of unlabelled carnitine. The exchange reaction was
stopped after 1 min by adding 1 mM mersalyl. For other experi-
mental details see under Section 2. Values are expressed as
means"S.E.M. for four separate experiments with two rats for
each group.
 .case exchanges cytosolic medium acylcarnitine or
free carnitine for carnitine in the mitochondrial ma-
trix. The rates of carnitine–carnitine exchange were
 .dramatically decreased around 38% in mitochondria
from hypothyroid rats as compared to the values
obtained with mitochondria prepared from control
 .rats Fig. 1 . These lowered-rates of carnitine–carni-
tine exchange in hypothyroid rats were brought back
to the level of control rats following treatment of
hypothyroid rats with T hormone.3
To determine whether this decreased activity re-
flects an altered affinity of the translocase for carni-
tine andror a decrease in the maximal exchange
velocity, the kinetics of the exchange were analysed
by studying the dependence on substrate concentra-
tion of the rate of carnitine efflux by carnitine-pre-
Table 2
Kinetic parameters of carnitine–carnitine exchange in heart mito-
chondria isolated from control, hypothyroid and hypothyroidq
T -treated rats3
Animals K Vm max
 .  .mM nmolrminrmg protein
Control 1.74"0.21 1.25"0.18
aHypothyroid 1.86"0.28 0.77"0.14
HypothyroidqT 1.61"0.24 1.31"0.193
a P -0.05 vs. control.
The K and V values for carnitine–carnitine exchange werem max
calculated from double reciprocal plots of the rates of intramito-
w14 xchondrial C -carnitine efflux versus external added unlabelled
 .carnitine ranging from 0.5 to 20 mM . For other experimental
details see to the legend of Fig. 1 and under Section 2. Each
value represents the mean"S.E.M. obtained for four separate
experiments with three rats for each group.
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Fig. 2. Rates of carnitine–palmitoylcarnitine exchange in heart
mitochondria isolated from control, hypothyroid and hypothyroid
qT -treated rats. Rates of carnitine–palmitoylcarnitine exchange3
w14 xby rat heart mitochondria were measured by addition of C -
carnitine loaded mitochondria to 0.5 ml of basal medium contain-
ing various concentrations of palmitoylcarnitine. The exchange
reaction was stopped after 1 min by adding 1 mM mersalyl. For
other experimental details see under Section 2. Each values
represent the mean"S.E.M. for four separate experiments with
two rats for each group.
loaded mitochondria. The data reported in Table 2
demonstrate that the maximal velocity of the carni-
tine–carnitine exchange was significantly reduced in
mitochondria from hypothyroid rats, while the Km
for carnitine was unaffected. Treatment of hypothy-
roid rats with T hormone completely restored the3
maximal activity of the carnitine–carnitine exchange
to the value of control animals.
Carnitine–palmitoylcarnitine exchange represents
the physiological expression of the translocase activ-
ity in the pathway to oxidation of fatty acids. As
palmitoylcarnitine supported respiration is decreased
 .in mitochondria from hypothyroid rats see Table 1 ,
it seemed possible that decreased rates of exchange
of extramitochondrial palmitoylcarnitine for matrix
carnitine may be responsible for decline in palmitoyl-
carnitine oxidation. Therefore, the activity of carni-
tine–palmitoylcarnitine exchange was measured in
mitochondria from control and hypothyroid rats.
Palmitoylcarnitine was used at concentrations below
20 mM due to the membrane-active properties of the
palmitoylcarnitine micelles. As shown in Fig. 2, rates
of carnitine–palmitoylcarnitine exchange were signif-
icantly reduced, at all external palmitoylcarnitine
concentrations used, in heart mitochondria from hy-
pothyroid rats compared to the values of mitochon-
dria from control rats. These lowered rates of carni-
tine–palmitoylcarnitine exchange were reversed by
administration of T hormone to hypothyroid rats.3
A direct relationship between carnitine exchange
activity and matrix carnitine concentrations has been
w xsuggested 24 . Therefore, the depressed rates of car-
nitine exchange in hypothyroid mitochondria could
result from decreased matrix carnitine. To eliminate
the possibility that hypothyroid mitochondria were
w14 xdeficient in loaded level of C -carnitine which
might differ widely from control, we measured the
carnitine specific activities after loading of mitochon-
dria from these two groups of rats with 2 mM radiola-
belled carnitine. No significant differences in carni-
tine specific activity were seen in control versus
Table 3
 .Phospholipid content and phospholipid composition mol% in heart mitoplasts isolated from control, hypothyroid and hypothyroidqT -3
treated rats
Phospholipid class Control Hypothyroid HypothyroidqT3
 .Total phospholipid-P nmolrmg Protein 285"18 255"14 284"19i
aCardiolipin 22.2"2.1 14.2"1.8 22.8"2.2
bPhosphatidylethanolamine 35.8"2.7 38.8"3.9 35.2"3.7
bPhosphatidylcholine 40.2"2.8 44.9"3.7 40.2"3.6
Phosphatidylinositol 0.4"0.0 7 0.5"0.08 0.4"0.07
Phosphatidylserine 1.4"0.2 1.6"0.3 1.4"0.2
a P-0.005.
b P-0.01 vs. control.
For phospholipid extraction and analysis, see Section 2. Each value represents the mean"S.E.M. obtained for four experiments with two
rats of each group.
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Table 4
Pattern of fatty acids in heart mitoplasts isolated from control,
hypothyroid and hypothyroidqT -treated rats3
 .Fatty acids Distribution mol%
Control Hypothyroid HypothyroidqT3
16:0 20.2"1.2 21.5"1.6 19.8"1.1
16:1 6.3"0.5 7.2"0.8 6.7"0.5
18:0 18.2"1.9 16.1"1.2 18.8"1.7
a18:1 12.6"1.1 6.7"0.3 12.5"1.1
18:2 31.9"2.8 28.3"1.9 32.1"2.8
a20:4 10.8"0.9 20.2"1.4 10.1"0.9
Extraction and analysis of fatty acids in mitoplast preparations
were carried out as described in Section 2. Each value represents
the mean"S.E.M. obtained for four separate experiments with
two rats for each group.
a P -0.01 vs. control.
hypothyroid rats specific activity 7,140"1,145 and
7,098"1,152 dpmrnmol in control and hypothyroid
.rats, respectively .
It has been reported that cardiolipin, a phospho-
lipid located at the level of the inner mitochondrial
membrane is essential for the functioning of the
isolated carnitine–acylcarnitine translocase protein
reconstituted in artificial membranes such as lipo-
w xsomes 8,9 . Thus, changes in mitochondrial cardi-
olipin content may affect the carnitine translocase
activity in situ. As the carnitine translocase protein is
located at the level of the inner mitochondrial mem-
brane, the phospholipid composition of mitoplasts
isolated from control, hypothyroid and hypothyroid
 .qT -treated rats was analysed see Table 3 . The3
total mass of mitochondrial phospholipids was no
significantly changed in mitoplast preparations of
either of these types of rats. Although the majority of
the individual phospholipid classes demonstrated no
appreciable differences in the mole percent composi-
 .tion, cardiolipin decreased significantly 36% in mi-
toplasts from hypothyroid animals. The decreased
level of cardiolipin in mitoplast preparation from
hypothyroid rats was restored to the level of control
rats by treating the hypothyroid rats with thyroid
hormone.
Chemical changes in the mitochondrial inner mem-
brane lipid composition were further investigated by
analysing the fatty acid patterns in these mitoplast
preparations. Alterations in fatty acid distribution
were observed in mitoplast preparations from hy-
pothyroid rats. In particular, a decrease in oleic acid
 .  .18:1 and an increase in arachidonic acid 20:4
were observed in the hypothyroid state. These differ-
ences were eliminated by administration of T hor-3
 .mone to hypothyroid rats Table 4 .
The fatty acid patterns of cardiolipin, phos-
phatidylcholine and phosphatidylethanolamine, iso-
lated by HPLC, revealed no substantial changes in
mitoplast preparations from control and hypothyroid
 .rats Table 5 .
Table 5
Fatty acid patterns of cardiolipin, phosphatidylcholine and Phosphatidylethanolamine in cardiac mitoplasts isolated from control and
hypothyroid rats
 .Fatty acids Distribution mol%
Cardiolipin Phosphatidylcholine Phosphatidylethanolamine
Control Hypothyroid Control Hypothyroid Control Hypothyroid
16:0 5.2"0.4 5.0"0.5 12.2"1.0 12.1"1.2 18.4"1.2 18.2"1.4
16:1 1.5"0.3 2.3"0.2 18.2"1.9 17.8"1.7 2.8"0.4 3.7"0.3
18:0 1.4"0.2 2.1"0.2 18.2"1.7 18.4"1.9 14.7"1.3 14.9"1.5
18:1 3.4"0.7 3.5"0.8 8.2"0.9 7.9"0.7 16.4"1.7 16.1"1.6
18:2 84.9"6.5 82.5"6.8 10.1"1.2 8.4"0.8 16.2"2.0 15.3"2.0
20:3 1.4"0.2 1.6"0.4 2.8"0.3 3.0"0.4 3.6"0.4 4.0"0.4
20:4 1.2"0.1 1.6"0.3 23.5"4.3 25.2"4.2 16.5"2.9 16.4"2.2
22:6 1.0"0.2 1.4"0.3 6.8"0.2 7.2"0.3 11.4"0.1 11.4"0.3
Extraction and analysis of fatty acids in mitoplast preparations were carried out as described in Section 2. Each value represents the
mean"S.E.M. obtained for four separate experiments with two rats for each group.
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4. Discussion
The present study demonstrates that cardiac mito-
chondrial fatty acid oxidation is significantly de-
pressed in hypothyroid animals. In fact, the results
presented herein show that the rates of palmitoylcar-
nitine, palmitoyl–CoAqcarnitine and acetylcarnitine
 .supported respiration are depressed around 35% in
heart mitochondria from hypothyroid rats. The oxida-
tion of all these substrates depends on the exchange
of carnitine and acylcarnitine across the mitochon-
drial inner membrane and so the activity of this
process has been examined and found to be dimin-
 .ished around 38% . The observed correlation be-
tween depressed respiratory rates and low transloca-
tion activity in mitochondria from hypothyroid rats
suggests that respiratory rate limitation may occur, at
least in part, by inhibition of this mitochondrial trans-
port sequence, although a contribution of carnitine
acyltransferase activity to this effect cannot be ex-
cluded.
Treatment of hypothyroid rats with T hormone3
restored the lowered-rates of fatty acid oxidation and
carnitine–acylcarnitine exchange to the level of con-
trol rats. This demonstrates that the inhibitory effect
induced by experimental hypothyroidism on the car-
nitine translocase is fully reversible, thus, excluding
any unspecific or irreversible effect of this pathologi-
cal state on carnitine carrier molecule itself or on the
intactness of the mitochondrial membranes.
The analysis of the kinetic parameters of the carni-
tine translocase, reported in Table 2, indicates that
the V of this process is depressed in mitochondriamax
from hypothyroid rats, while the affinity of carnitine
for its carrier system remains unchanged. The re-
duced mitochondrial carnitine translocase activity in
hypothyroid rats could be due to a modification of
the lipid surrounding of the carnitine carrier molecule
in the membrane, as proposed for other membrane-
w xassociated transport systems 10,11,25–27 . Among
lipid species, cardiolipin has a highly specialised
physiological distribution, being almost exclusively
located at the level of the inner mitochondrial mem-
w x w xbrane 28,29 where it is biosynthesised 30,31 . It
has been reported that cardiolipin is specifically re-
quired for full functioning of the isolated carnitine–
acylcarnitine translocase activity reconstituted in li-
w xposomes 8,9 . Moreover, in intact mitochondria of
rat liver and heart, the carnitine translocase activity
was markedly inhibited by micromolar concentration
w xof doxorubicin 9 , a specific cardiolipin-binding agent
w x32 . If this in vitro requirement of cardiolipin reflects
the in vivo situation, then changes in the cardiolipin
level in the mitochondrial inner membrane may affect
the activity of the carnitine–acylcarnitine translocase.
The results reported in Table 3 document a marked
 .and almost specific decrease around 36% in the
cardiolipin content in the inner mitochondrial mem-
brane from hypothyroid rats. Interestingly, the lower
content of cardiolipin in mitoplast preparations from
hypothyroid rats is brought back to the level of
control rats by treatment of hypothyroid rats with T3
hormone. These changes in mitochondrial cardiolipin
content are quantitatively associated to parallel
changes in carnitine–acylcarnitine translocase activ-
ity, which is reduced in mitochondria from hypothy-
roid rats and restored to normal level in mitochondria
from hypothyroidqT -treated rats. These results3
suggest that the observed decline in the carnitine
translocase activity in mitochondria from hypothyroid
rats may be mainly ascribed to a lower cardiolipin
content in the mitochondrial inner membrane.
The activity of other mitochondrial anion carrier
systems and enzymes has been shown to be reduced
in the hypothyroid state such as ADPrATP carrier
w x w x w x25,33,34 , pyruvate 10 , phosphate translocator 11
w xand cytochrome oxidase 35 , all protein systems
which exhibit a specific requirement of cardiolipin
for their full activity. Interestingly, it has been re-
cently reported in literature that the biosynthesis of
cardiolipin in mitochondria is under thyroid hormone
w xregulation 12,13 . Therefore, a decrease in the cardi-
olipin level in cardiac mitochondrial inner membrane
of hypothyroid animals, due probably to an alteration
w xin the cardiolipin synthase activity 12 , may repre-
sent the molecular mechanism responsible for the
decline in the activity of all these membrane-associ-
ated transport systems and cytochrome oxidase in this
physiopathological state.
Long chain fatty acids represent, together with
pyruvate, the major substrate for energy production in
the working heart. The carnitine–acylcarnitine
translocase may play a crucial role, together with
carnitine acyltransferase enzymes, in the regulation of
heart energy metabolism by facilitating the uptake of
fatty acid through the mitochondrial inner membrane.
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The large and significant decrement in carnitine–
acylcarnitine translocase activity and in fatty acid
oxidation, observed in mitochondria from hypothy-
roid rats, may be relevant to the pathology of hypo-
thyroidism in terms of decreased cardiac mitochon-
drial oxidative capacity and energy production typical
of the hypothyroid state.
Acknowledgements
This work has been accomplished with funds from
 .Ministero Pubblica Istruzione MURST 60% and
Consiglio Nazionale delle Ricerche. The authors thank
Mr. L. Gargano for the expert management of experi-
mental animals.
References
w x  .1 F.L. Hoch, Prog. Lipid Res. 27 1988 199–270.
w x  .2 J.R. Neely, H.E. Morgan, Annu. Rev. Physiol. 36 1974
413–459.
w x  .3 J. Bremer, Physiol. Rev. 63 1983 1421–1467.
w x  .4 S.V. Pande, Proc. Natl. Acad. Sci. U.S.A. 72 1975 883–
887.
w x  .5 R.R. Ramsay, P.K. Tubbs, FEBS Lett. 54 1975 21–25.
w x  .6 S.V. Pande, R. Parvin, J. Biol. Chem. 251 1976 6683–
6691.
w x  .7 J.A. Idell-Wenger, J. Biol. Chem. 256 1981 5597–5603.
w x8 C. Indiveri, A. Tonazzi, G. Prezioso, F. Palmieri, Biochim.
 .Biophys. Acta 1065 1991 231–238.
w x  .9 H. Noel, S.V. Pande, Eur. J. Biochem. 155 1986 99–102.
w x10 G. Paradies, F.M. Ruggiero, Arch. Biochem. Biophys. 269
 .1989 595–602.
w x11 G. Paradies, F.M. Ruggiero, P. Dinoi, Biochim. Biophys.
 .Acta 1070 1991 180–186.
w x  .12 K.Y. Hostetler, Biochim. Biophys. Acta 1086 1991 139–
140.
w x13 S.G. Cao, P. Cheng, A. Angel, G.M. Hatch, Biochim.
 .Biophys. Acta 1256 1995 241–244.
w x  .14 R. Parvin, S.V. Pande, J. Biol. Chem. 254 1979 5423–
5429.
w x15 G. Paradies, F.M. Ruggiero, G. Petrosillo, E. Quagliariello,
 .FEBS Lett. 397 1996 260–262.
w x  .16 R.G. Hansford, Biochem. J. 170 1978 285–295.
w x17 G. Paradies, F.M. Ruggiero, G. Petrosillo, M.N. Gadaleta,
 .E. Quagliariello, Mech. Ageing Dev. 84 1995 103–112.
w x18 D.F. Pauly, S.B. Yoon, J.B. McMillin, Am. J. Physiol. 253
 .1987 H1557–H1565.
w x  .19 M.E. Laker, P.A. Mayer, Biochem. J. 196 1990 247–256.
w x  .20 G. Paradies, Biochim. Biophys. Acta 766 1984 446–450.
w x21 R. Hovius, H. Lambrechts, K. Nicolay, B. de Kruijff, Biocim.
 .Biophys. Acta 1021 1990 217–226.
w x  .22 E.G. Bligh, W.J. Dyer, Can. J. Biochem. Physiol. 37 1959
911–917.
w x23 F.M. Ruggiero, C. Landriscina, G.V. Gnoni, E. Quagliariello,
 .Lipids 19 1984 171–178.
w x  .24 S.V. Pande, R. Parvin, J. Biol. Chem. 255 1980 2994–
3001.
w x25 G. Paradies, F.M. Ruggiero, Biochim. Biophys. Acta 935
 .1988 79–86.
w x26 G. Paradies, F.M. Ruggiero, Arch. Biochem. Biophys. 278
 .1990 425–430.
w x27 G. Paradies, F.M. Ruggiero, Biochim. Biophys. Acta 1019
 .1990 133–136.
w x  .28 G. Daum, Biochim. Biophys. Acta 822 1985 1–42.
w x  .29 F.L. Hoch, Biochim. Biophys. Acta 1113 1992 71–133.
w x30 K.Y. Hostetler, H. van den Bosch, Biochim. Biophys. Acta
 .260 1972 380–386.
w x  .31 G.M. Hatch, Biochem. J. 297 1994 201–208.
w x32 E. Goormaghtigh, P. Chatelain, J. Caspers, J.M. Ruyss-
 .chaert, Biochim. Biophys. Acta 597 1980 1–14.
w x  .33 Y.D. Chen, F.L. Hoch, Arch. Biochem. Biophys. 181 1977
470–483.
w x34 I.T. Mak, E. Shrago, C.E. Elson, Arch. Biochem. Biophys.
 .226 1983 317–323.
w x35 G. Paradies, F.M. Ruggiero, P. Dinoi, G. Petrosillo, E.
 .Quagliariello, Arch. Biochem. Biophys. 307 1993 91–95.
